InfuSystem (INFU) Competitors $8.00 -0.14 (-1.72%) (As of 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends INFU vs. IRMD, OFIX, SRDX, SIBN, KIDS, TMCI, CLPT, TCMD, DCTH, and ANGOShould you be buying InfuSystem stock or one of its competitors? The main competitors of InfuSystem include Iradimed (IRMD), Orthofix Medical (OFIX), Surmodics (SRDX), SI-BONE (SIBN), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), ClearPoint Neuro (CLPT), Tactile Systems Technology (TCMD), Delcath Systems (DCTH), and AngioDynamics (ANGO). These companies are all part of the "surgical & medical instruments" industry. InfuSystem vs. Iradimed Orthofix Medical Surmodics SI-BONE OrthoPediatrics Treace Medical Concepts ClearPoint Neuro Tactile Systems Technology Delcath Systems AngioDynamics Iradimed (NASDAQ:IRMD) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment. Which has more risk & volatility, IRMD or INFU? Iradimed has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Do institutionals & insiders have more ownership in IRMD or INFU? 92.3% of Iradimed shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 37.1% of Iradimed shares are owned by insiders. Comparatively, 10.2% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, IRMD or INFU? Iradimed has higher earnings, but lower revenue than InfuSystem. Iradimed is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIradimed$65.56M10.61$17.19M$1.4637.61InfuSystem$132.78M1.28$870K$0.06133.67 Does the media refer more to IRMD or INFU? In the previous week, Iradimed had 2 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for Iradimed and 0 mentions for InfuSystem. InfuSystem's average media sentiment score of 0.00 beat Iradimed's score of -1.00 indicating that InfuSystem is being referred to more favorably in the news media. Company Overall Sentiment Iradimed Negative InfuSystem Neutral Does the MarketBeat Community believe in IRMD or INFU? Iradimed received 246 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 64.78% of users gave Iradimed an outperform vote. CompanyUnderperformOutperformIradimedOutperform Votes25264.78% Underperform Votes13735.22% InfuSystemOutperform Votes6100.00% Underperform VotesNo Votes Is IRMD or INFU more profitable? Iradimed has a net margin of 26.12% compared to InfuSystem's net margin of 1.12%. Iradimed's return on equity of 23.99% beat InfuSystem's return on equity.Company Net Margins Return on Equity Return on Assets Iradimed26.12% 23.99% 20.45% InfuSystem 1.12%2.78%1.41% Do analysts rate IRMD or INFU? Iradimed presently has a consensus target price of $60.00, indicating a potential upside of 9.27%. InfuSystem has a consensus target price of $13.00, indicating a potential upside of 62.09%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than Iradimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iradimed 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00InfuSystem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00 SummaryIradimed beats InfuSystem on 11 of the 19 factors compared between the two stocks. Ad StocksToTradeLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!Click here to review Tim’s special Holiday offer before it’s too late. Get InfuSystem News Delivered to You Automatically Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INFU vs. The Competition Export to ExcelMetricInfuSystemSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$170.54M$4.32B$5.17B$19.10BDividend YieldN/A41.46%4.96%3.63%P/E Ratio133.6925.0987.1440.30Price / Sales1.2851.101,125.7518.59Price / Cash14.3743.3543.2721.25Price / Book3.257.024.825.26Net Income$870,000.00$13.64M$120.07M$988.83M7 Day Performance-1.60%1.82%1.02%0.44%1 Month Performance-9.89%-2.74%16.06%-5.30%1 Year PerformanceN/A36.79%28.43%11.36% InfuSystem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INFUInfuSystem1.6256 of 5 stars$8.00-1.7%$13.00+62.5%-22.8%$170.11M$132.78M133.36499IRMDIradimed4.3622 of 5 stars$53.88-1.4%$60.00+11.4%+15.2%$682.82M$71.31M36.90110Short Interest ↑News CoverageOFIXOrthofix Medical3.1625 of 5 stars$17.46+0.2%$23.00+31.7%+30.0%$667.22M$784.25M-5.581,634Short Interest ↓News CoverageSRDXSurmodics4.4945 of 5 stars$39.36-1.0%$50.00+27.0%+8.5%$563.87M$126.08M-48.59376SIBNSI-BONE4.4031 of 5 stars$13.15-0.8%$23.00+74.9%-34.6%$551.49M$157.04M-14.29350Positive NewsKIDSOrthoPediatrics4.0763 of 5 stars$22.38flat$39.00+74.3%-29.6%$541.95M$189.67M-18.19200TMCITreace Medical Concepts1.7101 of 5 stars$6.94-0.3%$7.88+13.5%-45.3%$432.34M$202.86M-7.01250CLPTClearPoint Neuro0.7922 of 5 stars$14.66-5.7%$11.33-22.7%+132.0%$404.40M$30.43M-21.25110News CoveragePositive NewsGap DownTCMDTactile Systems Technology3.5721 of 5 stars$16.78-1.3%$23.00+37.1%+20.6%$402.67M$285.05M25.82980Gap DownDCTHDelcath Systems3.6403 of 5 stars$11.19+1.6%$21.50+92.1%+187.5%$357.79M$22.64M-8.2976Short Interest ↓News CoverageANGOAngioDynamics4.7523 of 5 stars$8.68-2.4%$12.00+38.2%+13.6%$352.70M$292.73M-1.43748Short Interest ↓ Related Companies and Tools Related Companies IRMD Competitors OFIX Competitors SRDX Competitors SIBN Competitors KIDS Competitors TMCI Competitors CLPT Competitors TCMD Competitors DCTH Competitors ANGO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:INFU) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | SponsoredThis Warning flashed just before the dot-com bust and the Great DepressionA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InfuSystem Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InfuSystem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
